Cargando…

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as standard therapies for advanced nonsmall cell lung cancer (NSCLC) patients with EGFR mutation positive. Because these targeted therapies could cause tumor necrosis and shrinkage, the purpose of the study is to sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xiaobo, Zhang, Yang, Ma, Yuxiang, Zhou, Ting, Zhang, Jianwei, Hong, Shaodong, Sheng, Jin, Zhang, Zhonghan, Yang, Yunpeng, Huang, Yan, Zhang, Li, Zhao, Hongyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979775/ https://www.ncbi.nlm.nih.gov/pubmed/27495021 http://dx.doi.org/10.1097/MD.0000000000004176

Ejemplares similares

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

(125)I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy
por: Xiang, Zhanwang, et al.
Publicado: (2015)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
por: Gürbüz, Mustafa, et al.
Publicado: (2022)

The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis
por: Luo, Hui, et al.
Publicado: (2017)

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study
por: Zhao, Tongwei, et al.
Publicado: (2016)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis
por: Li, Juan, et al.
Publicado: (2020)

The effect of the earliest COVID-19 outbreak on survival in uninfected advanced NSCLC patients receiving chemotherapy in Jiangsu Province, China: A retrospective cohort study
por: Lu, Heng, et al.
Publicado: (2023)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study
por: Hu, Nan, et al.
Publicado: (2015)

Recent death early warning value of ECG changes in patients with NSCLC
por: Liu, Qiong, et al.
Publicado: (2023)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT
por: Pan, Yi, et al.
Publicado: (2015)

A network meta-analysis: The best Yiqi Fuzheng Chinese herbal injections for use based on the NP regimen to treat NSCLC
por: Luo, Huiyan, et al.
Publicado: (2020)

Gastric and colonic metastasis from NSCLC: A very unusual case report
por: Catalano, Martina, et al.
Publicado: (2022)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

TCM therapies combined with chemotherapy for preventing recurrence and metastasis in postoperative II to IIIA NSCLC: A protocol for a systematic review and meta-analysis
por: Chen, Shuntai, et al.
Publicado: (2019)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy
por: Koh, Young W., et al.
Publicado: (2017)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
por: Qi, Nan, et al.
Publicado: (2016)

Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients
por: Tang, Cuiping, et al.
Publicado: (2022)

Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study
por: Shen-Tu, Yang, et al.
Publicado: (2017)

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
por: Ding, Lin, et al.
Publicado: (2016)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
por: Lin, Chia-Ying, et al.
Publicado: (2019)

Construction of a 5 immune-related lncRNA-based prognostic model of NSCLC via bioinformatics
por: Huang, Ya-jie, et al.
Publicado: (2021)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uft1du7fj488hqs1agjkknmhs1